Oxadiazoles (including Hydrogenated) Patents (Class 514/364)
-
Patent number: 10117434Abstract: Provided herein are aqueous suspension concentrate compositions comprising biologically active 3,5-disubstituted-1,2,4-oxadiazoles or salts thereof that are useful, for example, in the control of nematodes.Type: GrantFiled: December 4, 2013Date of Patent: November 6, 2018Assignee: Monsanto Technology LLCInventors: Yiwei Ding, Shaun Raj Selness, Urszula J. Slomczynska
-
Patent number: 10034863Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.Type: GrantFiled: October 12, 2016Date of Patent: July 31, 2018Assignee: PTC Therapeutics, Inc.Inventors: Samit Hirawat, Langdon Miller
-
Patent number: 10034864Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.Type: GrantFiled: February 27, 2017Date of Patent: July 31, 2018Assignees: Incyte Holdings Corporation, Incyte CorporationInventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
-
Patent number: 10028939Abstract: The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.Type: GrantFiled: March 14, 2016Date of Patent: July 24, 2018Assignee: PTC Therapeutics, Inc.Inventors: Neil G. Almstead, Peter Seongwoo Hwang, Young-Choon Moon
-
Patent number: 9994559Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RAR?) (e.g., RAR?2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR? (e.g., RAR?2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR? (e.g., RAR?2), that are ameliorated by the activation of RAR? (e.g., RAR?2), etc., including, e.g., neurological injuries such as spinal cord injuries.Type: GrantFiled: December 16, 2015Date of Patent: June 12, 2018Assignee: KING'S COLLEGE LONDONInventors: Alan David Borthwick, Mark Trevor Mills, Jane Theresa Brown, Jonathan Patrick Thomas Corcoran, Maria Beatriz De Castro Vasconcelos Goncalves, Sarkis Barret Kalindjian
-
Patent number: 9926275Abstract: The present technology relates to compounds and compositions of Formulas I, II, VII, and VIII, and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of addiction, metabolic syndrome, obesity, and/or a CB1 receptor-mediated disorder.Type: GrantFiled: August 22, 2014Date of Patent: March 27, 2018Assignee: Northeastern UniversityInventors: Ganeshsingh Arjunsingh Thakur, Ritesh B. Tichkule, Pushkar Mukund Kulkarni, Abhijit Raghunath Kulkarni
-
Patent number: 9913829Abstract: The present invention relates to the compound of formula (I) for use in the treatment of a nonsense-mutation-mediated genetic disease.Type: GrantFiled: July 29, 2011Date of Patent: March 13, 2018Assignees: UNIVERSITE DE DROIT ET DE SANTE DE LILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR DE LILLEInventors: Fabrice Lejeune, Benoit Deprez, Terence Beghyn, Sara Sofia Gonzalez-Hilarion
-
Patent number: 9902717Abstract: The present invention relates to a process for the preparation of Azilsartan Medoxomil Potassium. The invention further relates to novel highly crystalline polymorph of Azilsartan Medoxomil Potassium and composition comprising it. The invention provides thermostable highly crystalline polymorph of Azilsartan Medoxomil Potassium and process to produce a composition comprising the novel highly crystalline polymorph of Azilsartan Medoxomil Potassium.Type: GrantFiled: March 21, 2016Date of Patent: February 27, 2018Assignee: UNICHEM LABORATORIES LIMITEDInventors: Dhananjay G. Sathe, Dnyaneshwar V. Gawas, Sashikant D. Metkar
-
Patent number: 9890126Abstract: Antibacterial and antimalarial IspF inhibitor compounds and compositions are described. Methods include administering described compounds and compositions to treat bacterial or parasitic infections and to inhibit parasite or bacterial growth.Type: GrantFiled: March 9, 2016Date of Patent: February 13, 2018Assignees: Board of Trustees of Northern Illinois University, Beryllium Discovery Corp.Inventors: Timothy J. Hagen, Zheng Zhang, Zachary Lazowski, Michael Clare, Darren W. Begley
-
Patent number: 9873677Abstract: Provided herein are pharmaceutical compositions, which comprise a 1,2,4-oxadiazole benzoic acid or a pharmaceutically acceptable salt thereof. Further provided herein are certain pharmaceutically acceptable salts of a 1,2,4-oxadiazole benzoic acid and methods for making the same. Further provided herein are methods of treating or preventing a disease associated with a nonsense mutation or a premature stop codon, comprising administering such pharmaceutical compositions or pharmaceutically acceptable salts to a patient having a disease associated with a nonsense mutation or a premature stop codon.Type: GrantFiled: March 5, 2015Date of Patent: January 23, 2018Assignee: PTC Therapeutics, Inc.Inventors: Marla L. Weetall, Ellen Welch, Mandar V. Dali, James Takasugi
-
Patent number: 9862710Abstract: The present invention relates to novel oxazolidinone compounds of general formula (I) having antibiotic activity also against multiresistant bacterial strains.Type: GrantFiled: March 15, 2013Date of Patent: January 9, 2018Assignees: ISTITUTO EURO MEDITERRANEO DI SCIENZA E TECNOLOGIA, UNIVERSITA' DEGLI STUDI DI MILANO—BICOCCAInventors: Rosario Musumeci, Clementina Elvezia Anna Cocuzza, Cosimo Gianluca Fortuna, Andrea Pace, Antonio Palumbo Piccionello
-
Patent number: 9861617Abstract: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.Type: GrantFiled: November 13, 2015Date of Patent: January 9, 2018Assignee: PTC Therapeutics, Inc.Inventors: Gary Mitchell Karp, Seongwoo Hwang, Guangming Chen, Neil Gregory Almstead, Young-Choon Moon
-
Patent number: 9855250Abstract: One example embodiment relates to a method of treating lung cancer by administering a compound of formula I to a subject in need thereof. Another embodiment relates to a method to treat Non-Small Cell Lung Cancer (NSCLC) by administering the compound of formula I to a patient.Type: GrantFiled: November 14, 2016Date of Patent: January 2, 2018Assignee: Macau University of Science and TechnologyInventors: Liang Liu, Elaine Lai-Han Leung, Xiao-Jun Yao, Vincent Kam-Wai Wong, Xi Chen
-
Patent number: 9849146Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.Type: GrantFiled: June 13, 2012Date of Patent: December 26, 2017Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
-
Patent number: 9789094Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.Type: GrantFiled: April 7, 2016Date of Patent: October 17, 2017Assignees: Incyte Holdings Corporation, Incyte CorporationInventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
-
Patent number: 9771338Abstract: The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: GrantFiled: October 20, 2016Date of Patent: September 26, 2017Assignee: Auirgene Discovery Technologies LimitedInventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
-
Patent number: 9737513Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.Type: GrantFiled: November 8, 2016Date of Patent: August 22, 2017Assignee: PTC Therapeutics, Inc.Inventors: Samit Hirawat, Langdon Miller
-
Patent number: 9737534Abstract: The present invention relates to compounds of Formula (I), along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).Type: GrantFiled: August 31, 2015Date of Patent: August 22, 2017Assignee: LUPIN LIMITEDInventors: Nageswara Rao Irlapati, Gokul Keruji Deshmukh, Vijay Pandurang Karche, Santosh Madhukar Jachak, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9604945Abstract: Derivatives of Sydnonimine and its analogues, which bind selectively to dopamine transporter (DAT) proteins are useful for treating and delaying the progression of disorders and illnesses that are alleviated by inhibiting dopamine reuptake.Type: GrantFiled: March 27, 2013Date of Patent: March 28, 2017Assignee: Caliper Life Sciences, Inc.Inventors: Hao Chen, Ming Liu, Qi Su, Manish Raisinghani
-
Patent number: 9550793Abstract: The present disclosure relates to a series of spirocyclic compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates, hydrates, N-Oxides, Co crystals and formulations thereof. The disclosure also relates to process of preparation of these spirocyclic compounds. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of acyl CoA diacyl glycerol acyltransferase 1 (DGAT1).Type: GrantFiled: October 1, 2013Date of Patent: January 24, 2017Assignee: Advinus Therapeutics LimitedInventors: Summon Koul, Debnath Bhuniya, Kasim Mookhtiar, Sandeep Bhosale, Suresh Kurhade, Keshav Naik, Ravikumar Velayutham, Videsh Salunkhe
-
Patent number: 9481658Abstract: An optical film including at least one compound represented by formula (1) is disclosed. In the formula, Y11, Y12 and Y13 each independently represent methine or a nitrogen atom; R11, R12 and R13 each independently represent formula (A), (B) or (C) or a hydrogen atom, provided that at least two of R11, R12 and R13 each independently represent formula (A), (B) or (C). In the formulae, L12, L22, and L32 each represent a 5-membered heterocyclic group.Type: GrantFiled: November 21, 2014Date of Patent: November 1, 2016Assignee: FUJIFILM CorporationInventors: Ryo Hamasaki, Hideyuki Nishikawa, Makoto Takahashi, Takashi Miyahara, Masuji Motoki, Masaaki Tsukase
-
Patent number: 9474743Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.Type: GrantFiled: March 21, 2014Date of Patent: October 25, 2016Assignee: PTC Therapeutics, Inc.Inventors: Samit Hirawat, Langdon Miller
-
Patent number: 9458126Abstract: Disclosed herein is a monomer for binding nano-metal, which is useful for the preparation of a conductor having increased conductivity with ensuring flexibility and transparency. Polymerization of the monomer for binding nano-metal provides a conductive polymer composite including a nano-metal rod. A method of preparing the conductive polymer composite is also provided.Type: GrantFiled: June 26, 2015Date of Patent: October 4, 2016Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Byung Hee Sohn, Young Kwan Lee, Yi Yoiung Yun, Won Jae Joo
-
Patent number: 9421192Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: November 6, 2015Date of Patent: August 23, 2016Assignee: Bristol-Myers Squibb CompanyInventors: Makonen Belema, Van N. Nguyen
-
Patent number: 9394264Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.Type: GrantFiled: February 27, 2015Date of Patent: July 19, 2016Assignee: Receptos, Inc.Inventors: Esther Martinborough, Marcus F. Boehm, Adam Richard Yeager, Junko Tamiya, Liming Huang, Enugurthi Brahmachary, Manisha Moorjani
-
Patent number: 9382217Abstract: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.Type: GrantFiled: June 23, 2014Date of Patent: July 5, 2016Assignee: The Scripps Research InstituteInventors: Edward Roberts, Hugh Rosen, Steven Brown, Miguel A. Guerrero, Xuemei Peng, Ramulu Poddutoori
-
Patent number: 9345244Abstract: The present invention relates to novel non-steroidal brassinosteroid mimetic derivatives, to processes and intermediates for preparing them, to plant growth regulator compositions comprising them and to methods of using them for controlling the growth of plants and/or promoting the germination of seeds.Type: GrantFiled: September 11, 2012Date of Patent: May 24, 2016Assignees: Syngenta Participations AG, Syngenta LimitedInventors: Pierre Joseph Marcel Jung, Joerg Leipner, Mathilde Denise Lachia, Alain De Mesmaeker, Matthew Murdoch Woodhead McLachlan
-
Patent number: 9320732Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.Type: GrantFiled: March 18, 2015Date of Patent: April 26, 2016Assignees: Incyte Corporation, Incyte Holdings CorporationInventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
-
Patent number: 9309206Abstract: The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.Type: GrantFiled: April 25, 2014Date of Patent: April 12, 2016Assignee: PTC Therapeutics, Inc.Inventors: Neil G. Almstead, Peter Seongwoo Hwang, Young-Choon Moon
-
Patent number: 9296747Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.Type: GrantFiled: October 10, 2014Date of Patent: March 29, 2016Assignee: Allergan, Inc.Inventors: Julie A. Wurster, Thomas C. Malone, Clarence Eugene Hull, III, Sandhya Rao, Rong Yang, Richard Yee
-
Patent number: 9289398Abstract: The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.Type: GrantFiled: March 29, 2007Date of Patent: March 22, 2016Assignee: PTC Therapeutics, Inc.Inventors: Neil Almstead, Guangming Chen, Samit Hirawat, Peter Seongwoo Hwang, Gary M. Karp, Langdon Miller, Young-Choon Moon, Hongyu Ren, James J. Takasugi, Ellen M. Welch, Richard G. Wilde, Paul Kennedy
-
Patent number: 9226919Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.Type: GrantFiled: October 11, 2007Date of Patent: January 5, 2016Assignee: PTC Therapeutics, Inc.Inventors: Samit Hirawat, Langdon Miller
-
Patent number: 9205088Abstract: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.Type: GrantFiled: January 28, 2015Date of Patent: December 8, 2015Assignee: PTC Therapeutics, Inc.Inventors: Gary Mitchell Karp, Seongwoo Hwang, Guangming Chen, Neil Gregory Almstead, Young-Choon Moon
-
Patent number: 9186407Abstract: The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an ?4?2 positive allosteric modulator, a method of using the same, and a related article of manufacture.Type: GrantFiled: April 5, 2011Date of Patent: November 17, 2015Assignee: AbbVie Inc.Inventors: Murali Gopalakrishnan, Marie P. Honore, Chih-Hung Lee, John Malysz, Jianguo Ji, Tao Li, Michael R. Schrimpf, Kevin B. Sippy, David J. Anderson
-
Patent number: 9187437Abstract: Disclosed are compounds of Formula (I): or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents; and R3, L1, L2, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.Type: GrantFiled: September 23, 2011Date of Patent: November 17, 2015Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Jagabandhu Das, Soo Sung Ko
-
Patent number: 9174980Abstract: The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R7, A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: January 29, 2013Date of Patent: November 3, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Alessandra Bartolozzi, Zhidong Chen, Jonathon Alan Dines, Ho Yin Lo, Pui Leng Loke, Alan Olague, Doris Riether, Heather Tye, Lifen Wu, Renee M. Zindell
-
Patent number: 9169242Abstract: The present invention relates to compounds that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC and to processes for preparing these compounds. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC by these compounds.Type: GrantFiled: October 31, 2011Date of Patent: October 27, 2015Assignee: LUPIN LIMITEDInventors: Nageswara Rao Irlapati, Gokul Keruji Deshmukh, Vijay Pandurang Karche, Santosh Madhukar Jachak, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9119843Abstract: Method of using dopamine reuptake inhibitors, e.g., sydnonimine derivatives, for the management of diabetic symptoms and associated complications or conditions, such as hyperglycemia and diabetic neuropathy.Type: GrantFiled: December 3, 2010Date of Patent: September 1, 2015Assignee: Caliper Life Sciences, Inc.Inventors: Hao Chen, Ming Liu, Malathi Sathyamoorthy, Qi Su, Lisa Leary, Wayne Shaobin Zhong
-
Patent number: 9108924Abstract: The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.Type: GrantFiled: September 20, 2012Date of Patent: August 18, 2015Assignee: Fresenius Kabi Oncology LimitedInventors: Bhuwan Bhaskar Mishra, Nikunj Shambhubhai Kachhadia, Vinod Singh Tomar, Saswata Lahiri
-
Patent number: 9096585Abstract: Described herein are Compounds, compositions comprising such Compounds, and the use of such Compounds and compositions as anti-viral agents. In one aspect, provided herein are methods of inhibiting viral replication using Compounds described herein or compositions thereof. In another aspect, provided herein are methods for preventing a symptom of a viral infection using a Compound, or a composition thereof. In another aspect, provided herein are methods of treating and/or managing viral infection using a compound or a composition thereof.Type: GrantFiled: May 31, 2011Date of Patent: August 4, 2015Assignee: Icahn School of Medicine at Mount SinaiInventors: Megan Shaw, Hans-Heinrich Hoffmann, Adolfo Garcia-Sastre, Peter Palese
-
Patent number: 9090600Abstract: The present invention provides fungicidal 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadiazol-5(4H)-one derivatives of formula (I) wherein A represents a pyridyl or thiazole group and X1, Y1 to Y5 represent independently different substituents.Type: GrantFiled: September 10, 2012Date of Patent: July 28, 2015Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christoph Braun, Haruko Sawada, Helene Lachaise, Stephane Brunet, Philippe Rinolfi, Christophe Dubost, Pierre-Yves Coqueron, Simon Maechling, Anne-Sophie Rebstock, Ulrike Wachendorff-Neumann
-
Patent number: 9050326Abstract: The present invention relates to a pharmaceutical composition containing a solid dispersion comprising an amide derivative or a salt thereof and a water-soluble polymer, wherein the pharmaceutical composition is not prepared by a melting method. The pharmaceutical composition contains the solid dispersion having an improved oral absorption, properties suitable for formulation, and an excellent stability.Type: GrantFiled: March 31, 2009Date of Patent: June 9, 2015Assignee: ASTELLAS PHARMA INC.Inventors: Masanori Kobayashi, Takuya Fukatsu, Kazunari Satou
-
Patent number: 9045442Abstract: Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.Type: GrantFiled: December 21, 2007Date of Patent: June 2, 2015Assignee: University of Notre Dame du LacInventors: Shahriar Mobashery, Peter I. O'Daniel, Mayland Chang
-
Publication number: 20150148346Abstract: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.Type: ApplicationFiled: January 28, 2015Publication date: May 28, 2015Applicant: PTC Therapeutics Inc.Inventors: Gary Mitchell Karp, Seongwoo Hwang, Guangming Chen, Neil Gregory Almstead, Young-Choon Moon
-
Publication number: 20150148384Abstract: Disclosed herein are novel A-ring epoxidized triterpenoid compounds and derivatives thereof, including those of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided.Type: ApplicationFiled: June 14, 2013Publication date: May 28, 2015Applicant: REATA PHARMACEUTICALS, INC.Inventors: Eric Anderson, Christopher F. Bender, Xin Jiang, Xiaofeng Liu, Haizhou Sun, Melean Visnick
-
Patent number: 9040568Abstract: This invention discloses a method of treatment of osteoarthritis pain by administration of a composition containing a nicotinic acetylcholine receptor ligand and a nicotinic acetylcholine receptor subtype ?4?2 allosteric modulator. The present application also relates to compositions comprising such compounds for use in treating pain and related disorders mediated by controlling neurotransmitter release in a subject.Type: GrantFiled: May 26, 2010Date of Patent: May 26, 2015Assignee: AbbVie Inc.Inventors: Murali Gopalakrishnan, Chih-Hung Lee, Jianguo Ji, Tao Li, Kevin B. Sippy
-
Patent number: 9040530Abstract: Provided are triazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.Type: GrantFiled: March 15, 2013Date of Patent: May 26, 2015Assignee: PORTOLA PHARMACEUTICALS, INC.Inventors: Zhaozhong J. Jia, Brian Kane, Jack Rose, Shawn M. Bauer, Yonghong Song, Qing Xu, Anjali Pandey
-
Publication number: 20150141418Abstract: The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production.Type: ApplicationFiled: January 26, 2015Publication date: May 21, 2015Applicant: PTC Therapeutics, Inc.Inventors: William Lennox, Hongyan Qi, Duck-Hyung Lee, Soongyu Choi, Young-Choon Moon
-
Publication number: 20150141474Abstract: The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.Type: ApplicationFiled: April 26, 2013Publication date: May 21, 2015Applicant: NOVARTIS AGInventors: Sejal Patel, Justin Mao, Qian Liu, Tyler Harrison, Rohit Duvadie, Xin Chen, Frederic Zecri
-
Publication number: 20150139915Abstract: Methods and compositions are described for reducing airway reactivity and the susceptibility to asthmatic bronchoconstriction that involve increasing sphingolipid content in airways and lungs of a mammalian subject.Type: ApplicationFiled: May 16, 2013Publication date: May 21, 2015Inventors: Stefan Worgall, Tilla S. Worgall